BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38556044)

  • 21. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
    Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
    Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway.
    Wang Y; Zhong Z; Ma M; Zhao Y; Zhang C; Qian Z; Wang B
    Front Pharmacol; 2022; 13():1081978. PubMed ID: 36686653
    [No Abstract]   [Full Text] [Related]  

  • 24. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.
    Zhang Y; Zou B; Tan Y; Su J; Wang Y; Xu J; Tao L; Zhou H; Liu L; Li X
    Pharmacol Res; 2019 Apr; 142():140-150. PubMed ID: 30797069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
    Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
    PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.
    Nakashima Y; Haneji T
    PLoS One; 2013; 8(9):e72033. PubMed ID: 24039733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective entry into mitosis 1 (Dim1) negatively regulates osteoclastogenesis by inhibiting the expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1).
    An D; Kim K; Lu W
    J Biol Chem; 2014 Aug; 289(35):24366-73. PubMed ID: 25023277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.
    Ha H; Shim KS; Kim T; Lee CJ; Park JH; Kim HS; Ma JY
    BMC Complement Altern Med; 2014 Sep; 14():352. PubMed ID: 25249312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation.
    Funaki Y; Hasegawa Y; Okazaki R; Yamasaki A; Sueda Y; Yamamoto A; Yanai M; Fukushima T; Harada T; Makino H; Shimizu E
    Yonago Acta Med; 2018 Mar; 61(1):8-18. PubMed ID: 29599617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
    Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
    J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis.
    Li CH; Lü ZR; Zhao ZD; Wang XY; Leng HJ; Niu Y; Wang MP
    Front Pharmacol; 2021; 12():781640. PubMed ID: 34955850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
    Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
    Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
    Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
    Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2E-Decene-4,6-diyn-1-ol-acetate inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signalling pathways.
    Park YR; Su XD; Shrestha SK; Yang SY; Soh Y
    Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):341-349. PubMed ID: 34729812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.
    Li Y; Shi Z; Jules J; Chen S; Kesterson RA; Zhao D; Zhang P; Feng X
    J Bone Miner Res; 2019 Oct; 34(10):1938-1951. PubMed ID: 31173390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.